Tumor Biology

, Volume 36, Issue 2, pp 1273–1278 | Cite as

The SIPA1 -313A>G polymorphism is associated with prognosis in inoperable non-small cell lung cancer

  • Agnieszka Gdowicz-Kłosok
  • Monika Giglok
  • Anna Drosik
  • Rafał Suwiński
  • Dorota Butkiewicz
Research Article

Abstract

Polymorphism in signal-induced proliferation-associated 1 (SIPA1) gene may contribute to the development of metastasis in human cancers. In this preliminary study, we examined the association of the SIPA1 -313A>G (rs931127) polymorphism with overall survival (OS) and progression-free survival (PFS) in 351 inoperable patients with non-small cell lung cancer (NSCLC) treated with radiotherapy or radiochemotherapy (curative or palliative). The GG homozygotes had significantly shorter PFS under codominant and recessive models in all patients (hazard ratio (HR) 1.47, p = 0.035, and HR 1.47, p = 0.022, respectively) and in advanced stage subgroup (HR 1.49, p = 0.037, and HR 1.48, p = 0.023, respectively). The GG genotype was also associated with reduced OS and PFS (codominant model: HR 2.41, p = 0.020, and HR 2.34, p = 0.020, respectively; recessive model: HR 2.16, p = 0.026, and HR 2.18, p = 0.022, respectively) in radiotherapy alone subgroup. Moreover, the SIPA1 -313GG was identified as an independent adverse prognostic factor for PFS in the cohort. Our results indicate, for the first time, that the SIPA1 -313A>G may have a prognostic role in unresected NSCLC making it a potential predictor of poor survival due to earlier progression.

Keywords

SIPA1 Polymorphism Survival Lung cancer Prognosis 

Notes

Acknowledgments

The authors thank Mrs. Z. Kołosza for providing the part of the epidemiological data as well as Mrs. I. Matuszczyk and Mrs. I. Domińczyk for their technical assistance. This work was supported by grant no. 2012/05/B/NZ5/01905 from Polish National Science Centre (NCN) and grant no. NN 403 290636 from Polish Ministry of Science and Higher Education (MNiSW).

Conflicts of interest

None

References

  1. 1.
    Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10 Suppl 1:S2.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kurachi H, Wada Y, Tsukamoto N, Maeda M, Kubota H, Hattori M, et al. Human SPA-1 gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rap1 and Rap2. Segregate expression profiles from a rap1GAP gene product. J Biol Chem. 1997;272:28081–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Shimizu Y, Hamazaki Y, Hattori M, Doi K, Terada N, Kobayashi T, et al. SPA-1 controls the invasion and metastasis of human prostate cancer. Cancer Sci. 2011;102:828–36.CrossRefPubMedGoogle Scholar
  4. 4.
    Ji K, Ye L, Toms AM, Hargest R, Martin TA, Ruge F, et al. Expression of signal-induced proliferation-associated gene 1 (SIPA1), a RapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. Cancer Genomics Proteomics. 2012;9:321–7.PubMedGoogle Scholar
  5. 5.
    Zhang Y, Gong Y, Hu D, Zhu P, Wang N, Zhang Q, et al. Nuclear SIPA1 activates integrin β1 promoter and promotes invasion of breast cancer cells. Oncogene. 2014. doi: 10.1038/onc.2014.36.Google Scholar
  6. 6.
    Akervall JA, Jin Y, Wennerberg JP, Zatterstrom UK, Kjellen E, Mertens F, et al. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer. 1995;76:853–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, et al. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat. 2010;121(2):347–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E, et al. Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol. 2010;116:539–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res. 2006;8:R16.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res. 2009;11:R75.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hsieh SM, Smith RA, Lintell NA, Hunter KW, Griffiths LR. Polymorphisms of the SIPA1 gene and sporadic breast cancer susceptibility. BMC Cancer. 2009;9:331.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pei R, Xu Y, Wei Y, Ouyang T, Li J, Wang T, et al. Association of SIPA1 545 C > T polymorphism with survival in Chinese women with metastatic breast cancer. Front Med. 2013;7:138–42.CrossRefPubMedGoogle Scholar
  13. 13.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5—a population-based study. Lancet Oncol. 2014;15:23–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Xie C, Yang L, Yang X, Yang R, Li Y, Qiu F, et al. Sipa1 promoter polymorphism predicts risk and metastasis of lung cancer in Chinese. Mol Carcinog. 2013;52 Suppl 1:E110–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Gaudet MM, Hunter K, Pharoah P, Dunning AM, Driver K, Lissowska J, et al. Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. Int J Cancer. 2009;124:1716–20.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet. 2005;37:1055–62.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yi SM, Li GY. The association of SIPA1 gene polymorphisms with breast cancer risk: evidence from published studies. Tumor Biol. 2014;35:441–5.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Agnieszka Gdowicz-Kłosok
    • 1
  • Monika Giglok
    • 2
  • Anna Drosik
    • 2
    • 3
  • Rafał Suwiński
    • 2
  • Dorota Butkiewicz
    • 1
  1. 1.Center for Translational Research and Molecular Biology of CancerM. Skłodowska-Curie Memorial Cancer Center and Institute of OncologyGliwicePoland
  2. 2.II Clinic of Radiotherapy and ChemotherapyM. Skłodowska-Curie Memorial Cancer Center and Institute of OncologyGliwicePoland
  3. 3.Department of Clinical OncologyM. Skłodowska-Curie Memorial Cancer Center and Institute of OncologyGliwicePoland

Personalised recommendations